Advicenne S.A. (EPA:ALDVI)

Market Cap	21.60M
Revenue (ttm)	5.27M
Net Income (ttm)	-6.46M
Shares Out	12.27M
EPS (ttm)	-0.53
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	325
Average Volume	10,041
Open	1.760
Previous Close	1.760
Day's Range	1.756 - 1.760
52-Week Range	0.827 - 2.390
Beta	1.27
RSI	49.47
Earnings Date	Sep 18, 2025

About Advicenne

Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases in France and internationally. The company offers Sibnayal for the treatment of metabolic disorders, distal renal tubular acidosis, and cystinuria. It also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or condition-causing anxiety unacceptable distress; and Levidcen, a galenic form of levetiracetam for the treatment of epileptic seizures. Advicenne S.A. wa...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 13
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALDVI

Financial Performance

In 2024, Advicenne's revenue was 5.27 million, a decrease of -0.51% compared to the previous year's 5.30 million. Losses were -6.46 million, -14.13% less than in 2023.